The drug paracetamol (N-acetyl-p-aminophenol; acetaminophen) caused a spurious increase in serum uric acid measured by phosphotungstic acid reduction methods. However, the increase was less than 0·12 mrnol/l at plasma levels of paracetamol found in overdosage (40 mg/IOO ml) and was small at therapeutic concentrations (less than 4 mg/IOO ml). It is concluded that few
patients with joint pain who have taken paracetamol as an analgesic will have clinically misleading values for serum uric acid.
The drug paracetamol is a freely available analgesic which may be taken by patients with joint pain in whom the possibility of a diagnosis of gout arises. It is of some concern that there have been conflicting reports of the effect of paracetamol on the measurement of uric acid by phosphotungstate reduction methods. Singh et al. (1972) found that the effect of therapeutic levels of paracetamol on serum uric acid was small. In contrast, Wilding and Heath (1975) found that measured serum uric acid was increased 0·12 mrnol/l by a single 1 g dose and 0,18-0,24 mmol/l by a 2 g dose and suggested that the effect in patients who had taken an overdose was so great that the phosphotungstate method might be used for rapid screening to assess the severi ty of poisoning. The present investigation was designed to resolve this conflict.
Patients and methods Simoes, 1965; Musser and Ortigoza, 1966) , phosphotungstic acid with urea/cyanide (Technicon method N-136), and phosphotungstic acid with sodium carbonate/tungstate (Brown and Freier, 1967) . All measurements were made on a Technicon AutoAnalyzer Model I. Serum paracetamol concentration was determined by the method of Dordoni et al. (1973) .
Fifteen clinical biochemistry laboratories in Yorkshire, using a variety of analytical methods, made blind measurements in duplicate of the uric acid concentrations of a pooled serum sample and of the same sample to which 40 mg/IOOml of paracetamol had been added. The specimens were distributed by post.
Results

IN VIVO STUDIES
Blood was collected from 30 patients with paracetamol overdosage immediately after they had been Overdose patients admitted to this hospital and, in 10 of them, on The serum uric acid and paracetamol concentrations subsequent occasions for up to four days. Serum in three of the 10 overdose patients with sequential paracetamol concentrations were determined irn-data are shown in Table 1 . The other seven patients mediately, and uric acid concentrations were showed a similar pattern. No change in the apparent determined after the specimens had been stored at uric acid concentration measured either by the -20 c e. phosphotungstic acid-hydroxylamine/tungstate or Blood was taken from two volunteers before and phosphotungstic acid-urea/cyanide method exceeded at half-, one-, and two-hour intervals after the 0·12 mmol/l, ingestion of 1 g of paracetamol, and serum concen-In the whole group of 30 overdose patients with trations of paracetamol and uric acid were deter-paracetamol levels up to 54 mg/l00 ml, the highest mined.
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Normal subjects
The serum uric acid levels measured by the phosphotungstic acid-urea/cyanide method in two subjects showed no detectable change in concentration after the ingestion of 1 g of paracetamol. These analytical results were confirmed in another laboratory using the standard Technicon phosphotungstic acidhydroxylamine/tungstate method on a Technicon SMA 12/60 analyser.
IN VITRO STUDIES
Aqueous solutions of paracetamol ranging from 10 to 100 mg/loo ml were measured for uric acid by each of the three phosphotungstic acid methods. The increase in apparent uric acid concentration was far greater with phosphotungstic acid-hydroxylamine/tungstate than with the other two methods, and for this and the urea/cyanide method the increment in apparent uric acid became smaller as the paracetamol concentration increased (Fig. 1) . The effect of adding increasing concentrations of paracetamol to a 0-4 rnmol/l aqueous solution of uric acid analysed by two methods is shown in Figure 2 . There was no measurable effect on the phosphotungstic acid-urea/cyanide method. Comparison of Fig. 2 with Fig. 1 shows that, with the phosphotungstic acid-hydroxylamine/tungstate method, the increment produced by 50 mg/loo ml of paracetamol added to 0·4 rnmolJl uric acid was smaller than that produced by 50 mg/loo m1 of paracetamol in water but was of the same order as that produced by adding a further 50 mg/loo ml of paracetamol to a 55 mg/loo ml solution (which would have had an apparent uric acid concentration of 0·4 mmol/l). Thus, in aqueous solution, the effect of added paracetamol diminishes the higher the starting apparent uric acid, whether this is due to paracetamol or to uric acid itself. This finding may well account for the relatively small increment in apparent uric acid measured by the phosphotungstic acid-hydroxylamine/tungstate method when up to 50 mg/loo ml of paracetamol was added to a serum pool (Fig. 3 ).
INTER-LABORATORY SURVEY
Aliquots of a pooled serum sample and of the same sample to which 40 mg/IOO ml of paracetamol had been added were distributed to 15 hospital biochemistry laboratories in Yorkshire among which a variety of methods (with a number of different wetting agents) are used for measuring uric acid (see Table 2 ). Even at this high serum paracetamol concentration no laboratory reported a spurious increase in serum uric acid concentration exceeding 0'12 mrnol/I (Table 2) , and no significant effect was observed by laboratories using phosphotungstic acid-sodium carbonate/tungstate or uricase methods.
Discussion
The changes with time in serum uric acid concen-tration in patients suffering from an overdose of paracetamol were small (Table 1) and insignificant by comparison with those found by Wilding and Heath (1975) . In addition, we have not been able to repeat the observation of these authors that an increase in uric acid concentration of 0'12 mmol/l occurred half an hour after the ingestion of only 1 g of paracetamol.
The effect of paracetamol on apparent uric acid concentration diminished as the paracetamol concentration in aqueous solution increased, in agreement with Singh et al. (1972) , who found that a 10-foid increase in paracetamol concentration in water only doubled the apparent uric acid concentration.
The addition of so mg/1oo ml of paracetamol to a serum pool with an initial uric acid concentration of 0·20 rnmol/I produced an increment of only about 0'14 mmol/l when measured by the phosphotungstic acid-hydroxylamine/tungstate method (Fig. 3) . In contrast, Wilding and Heath (1975) found that the addition of SO mg/loo ml of paracetamol to a pooled serum produced an apparent increase of serum uric acid greater than 4 mmolJI.
It is difficult to find a testable hypothesis that would explain why Wilding and Heath (1975) observed a marked effect of paracetamol on uric acid measured by phosphotungstic acid reduction while the present work and that of Singh et al. (1972) showed only a small effect.
One possibility is that the effect was magnified by some minor technical modification, such as the usc of a different wetting agent. For this reason a survey Re-examination of effect of paracetamol on serum uric acid measured by phosphotungstic acid reduction 99 was carried out in a number of laboratories in Yorkshire of the effect on measured serum uric acid of 40 mg/! 00 rn1 of paracetamol added to a serum pool. A patient with a plasma paracetamol concentration of this order 2 hours after taking an overdose is at the borderline of the region of high risk for the development of significant hepatotoxicity (Crome et al., 1976; Payne and Sheridan, 1976) . The largest effect, an increase of O'Lzmrnol/l, was reported by a laboratory using a phosphotungstic acid-ureal cyanide method with Technicon Wetting Agent A ( Table 2 ). Thus no laboratory in this survey found a large effect of a toxic level of paracetamol on measured uric acid. We have not been able to explain the large effects observed by Wilding and Heath (1975) , but this survey has shown that in practice it is a very uncommon analytical problem.
It seems unlikely that differences in the time between the preparation of specimens with added paracetamol and their analysis account for the differencesbetween our findings and those of Wilding and Heath (1975) . Specimens were analysed within a few hours in this laboratory but after a minimum of 24 hours at ambient temperature by the Yorkshire laboratories. In addition, we reanalysed a serum pool containing 40 mg/l00 ml of paracetamol after prolonged storage at 4°C and found no measurable increase in apparent uric acid.
Serum paracetamol concentrations, after the oral administration of 1 to 2 g, rise to less than 4 mg/ IOOmI (Gwilt et al., 1963; Heading et al., 1973; Rawlings et al., 1977) . At these paracetamol levels the effect on apparent serum uric acid is small with any of the phosphotungstic acid methods investigated here, and is particularly small with the phosphotungstic acid-sodium carbonate/tungstate method. It is concluded that few patients being investigated for gout, who have taken paracetamol as an analgesic and who have their serum uric acid concentration measured by a phosphotungstate reduction method, will have clinically misleading values for serum uric acid.
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